Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
OS is really all that counts, don’t you think? I’m sure patients would agree. :)
The share price was dropping like a rock before the presentation even began, let alone the PFS slide was shone.
Don’t you remember there was a YouTube video of a shareholder showing the share price tanking next to the presentation (that hadn’t even begun!) screen? That video (captured, I’m sure, by Northwest), will come in handy should the defense use “play that angle”.
Good approach, Captain! :)
Agreed, Mike. Looks like you’re long. Disgruntled, but long.
Or finance future trials.
First time, I think, that we’ve ever agreed on something? :)
Interesting.
lawsuit related.
Lol... I just saw this! Good one! :)
Good DD. :)
There are some who might say the FUD begins at the corner of Southeast 2nd Street and South Biscayne Blvd. in Miami (Citadel headquarters).
:)
There's still lots of work to be done... and then we'll take it higher. :)
That’s close to what I’m thinking as well.
Agreed. :)
Was it Henry’s post on Twitter re: the murcidencel name?
Brand Institute is, "The global leader in USAN/INN naming, partnering on 76% of USAN and 78% of INN drug name approvals!" #murcidencel #DCVax-L $NWBOhttps://t.co/u9BpJTBrf4 pic.twitter.com/u0zIUYYR9i
— Henry (@HenryMuney) October 27, 2023
I think he never went to college.
A revisit and a relook… that was actually rather clever.
My average is around .45 so I’m definitely in the money.
Have you?
I wondered who it was that attached that rider onto that bill:
Anyone think this is a shady attempt to sneak this rider into the House appropriations bill re: SEC funding to enforce against illegal actions like those in Harrington vs. CIBC World Markets Corp. and the $NWBO vs. 8 cheating MMs?
— Sentiment Stocks (@sentimentstock) October 11, 2023
Please go to the link and make yourself heard. https://t.co/4wMHjAiH0K
And now because Cognate was built on our dime, the company will have a manufacturer that’s ready to scale up and go upon signing the contracts.
So if that's how you think, then why continue to not only stick around, but make it your life's mission to stick around? By your lonesome, you've decided the trial has failed. What's the sense in continuing to poke a stick in it?
Haha… probably right! :)
The question remains, though, as to whether the Germans had any control patients enrolled in the trial. They certainly were allowed, for some still unknown reason, to have a lower lymphocyte count in the trial than the patients from the other countries.
Huh… I noticed, too, that Peter Thiel was there.
On that note of this Simian Virus 40 (SV40) DNA sequence recently found in the Pfizer Covid Vaccine…
Great analogy… great points… great post! :)
And had everyone long here sold and bought at exactly the perfect times as you claim to have done (due to your self-proclaimed incredible mental acumen), there would be no northwest bio as it would have disappeared into oblivion and bankruptcy. A less myopic and narcissistic view than you exhibit would see this.
I'm not onboard with the idea that Orbis is in the works. And I'm certainly long.
From April 19, 2023 (my only recent post on Orbis):
Given that this trial originally screened for both rapid and pseudoprogression patients (historically - rapidly progressing obviously would be the shortest living, and pseudoprogressors from chemo/rad often being the longest living GBM patients), and then initially even had a randomized arm for those who were determined to be pseudoprogressors from chemo/rad (originally to be 48 in number, but was removed from the trial when it numbered at 32), I would suggest there were very few in either the original treatment or control arms (since they were screened and removed).
The patients in this trial exhibiting pseudo progression were doing so after having received DCVax-L and THAT is what LL has reported on. She HAS NOT reported on the control patients in this trial having exhibited psPD prior to receiving DCVax-L. She HAS reported (many times) that DCVax-L often results in psPD.
Interesting, I think, that for a group of GBM patients that were screened to remove those exhibiting pseudo progression, there were so many patients exhibiting it.
I would add, that I believe at least few of the trials included in the ECA did not screen for psPD patients from chemo/rad and remove them. Most of them screened for rapidly progressing patients and excluded them.
There’s definitely a correlation with the dates; I suspect it’s coincidental, but I certainly don’t know that. The thought that comes to me is that it’d be better to have the application completely submitted by the time the Oral Argument on 11/14 takes place. In my mind, it would help with whatever argument Northwest presents, to be able to add that they’ve already submitted an application for approval to a regulator. So delaying the application’s submission for any reason due to Oral Argument doesn’t make sense for me at this time.
Maybe there’s a reason you’re seeing that I’m not?
Lol… no matter how much we prove this to not be the case to you, you continue to push this narrative.
It’s almost fascinating.
Right… and no need to apologize for typos. I make them all the time and most of us just read over them correcting them as we read, mentally.
Besides, ex has ensured we practice this art regularly with all of his spelling errors (lol) over the years.
Hmm… interesting analysis on your part. I don’t know who or where the consultant is from, but it’s very plausible they’re from the UK, given the regulator is the MHRA.
It's all in the long tail ... what made this particular group of patients live longer... more than doubling the number living to 5 years. It's not the complete resection (remember, a good many of these patients had significant residual disease). It's not IDH mutation (there were less IDH in the DCVax trial than many of the others), and it's not methylation (mOS was 30.2 for DCVax vs. 21.3 for the ECA).
But both sets, except those in the original control arm that did not cross over and you yourself have many times stated those patients likely died early as they were simply too sick to do so, received DCVax-L.
Reminds me of the old adage, "When you hear hoofbeats in the distance, look for horses, not zebras."